H.C. Wainwright analyst Yi Chen raised the firm’s price target on EyePoint (EYPT) to $23 from $22 and keeps a Buy rating on the shares following the Q2 report.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint reports Q2 EPS (85c), consensus (80c)
- EyePoint sees cash runway into 2027
- Buy Rating for EyePoint Pharmaceuticals: Duravyu’s Competitive Edge and Reliability Drive Investment Confidence
- Positive Buy Rating for EyePoint Pharmaceuticals Driven by Promising Clinical Trials and Market Valuation
- EyePoint’s wAMD study fully enrolled ahead of expectations, says RBC Capital